Singapore-based cancer biotech firm Hummingbird Bioscience to target inflammatory diseases with precision drugs

Hummingbird Bioscience recently received an award from the World Intellectual Property Organisation, the UN agency dedicated to innovation and creativity. - Hummingbird Bioscience/X via ST/ANN

SINGAPORE: Singapore-headquartered biotech firm Hummingbird Bioscience, known for developing antibodies for cancer, is turning its sights to drugs for immunology and inflammatory diseases, such as lupus and inflammatory bowel disease.

It will be adapting antibody-drug conjugates which it developed for cancer treatment to target these diseases.